Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive ...

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...

A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of ...

Hundreds of people with advanced bladder cancer across the UK can now receive three rather than six chemotherapy cycles following research by Queen Mary University of London which has led to a change ...

Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...

Shares of ImmunityBio, Inc. IBRX soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendekin alfa ...